[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "317 659 0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 642001, "exercisedValue": 0, "unexercisedValue": 3084960}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven L. Hoerter", "age": 53, "title": "Executive Chairperson", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Moraitis M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 28.43, "open": 28.76, "dayLow": 27.93, "dayHigh": 30.02, "regularMarketPreviousClose": 28.43, "regularMarketOpen": 28.76, "regularMarketDayLow": 27.93, "regularMarketDayHigh": 30.02, "payoutRatio": 0.0, "trailingPE": 3.89309, "forwardPE": -9.694806, "volume": 428609, "regularMarketVolume": 428609, "averageVolume": 1448514, "averageVolume10days": 864220, "averageDailyVolume10Day": 864220, "bid": 29.6, "ask": 30.03, "bidSize": 1, "askSize": 1, "marketCap": 1340782848, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 34.83, "allTimeHigh": 34.83, "allTimeLow": 4.807, "fiftyDayAverage": 22.7742, "twoHundredDayAverage": 14.241525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 949732736, "profitMargins": 0.0, "floatShares": 26204085, "sharesOutstanding": 44902302, "sharesShort": 4101744, "sharesShortPriorMonth": 4581641, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.0913, "heldPercentInsiders": 0.02726, "heldPercentInstitutions": 1.06564, "shortRatio": 5.07, "shortPercentOfFloat": 0.146, "impliedSharesOutstanding": 44902302, "bookValue": 8.667, "priceToBook": 3.4452522, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -80495000, "trailingEps": 7.67, "forwardEps": -3.08, "enterpriseToEbitda": -10.48, "52WeekChange": 0.485371, "SandP52WeekChange": 0.13613915, "quoteType": "EQUITY", "currentPrice": 29.86, "targetHighPrice": 80.0, "targetLowPrice": 18.0, "targetMeanPrice": 58.625, "targetMedianPrice": 61.5, "recommendationMean": 1.55556, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 391672992, "totalCashPerShare": 8.723, "ebitda": -90624000, "totalDebt": 623000, "quickRatio": 32.6, "currentRatio": 32.955, "debtToEquity": 0.161, "returnOnAssets": -0.16643, "returnOnEquity": -0.24433, "freeCashflow": -50834752, "operatingCashflow": -77685000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "earningsCallTimestampStart": 1754564400, "earningsCallTimestampEnd": 1754564400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 7.67, "epsForward": -3.08, "epsCurrentYear": -2.56429, "priceEpsCurrentYear": -11.644548, "fiftyDayAverageChange": 7.0858, "fiftyDayAverageChangePercent": 0.3111328, "twoHundredDayAverageChange": 15.618476, "twoHundredDayAverageChangePercent": 1.0966856, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1765581518, "regularMarketTime": 1765573202, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 5.0299, "regularMarketPrice": 29.86, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "postMarketChangePercent": -1.9423976, "postMarketPrice": 29.28, "postMarketChange": -0.5799999, "regularMarketChange": 1.43, "regularMarketDayRange": "27.93 - 30.02", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1448514, "fiftyTwoWeekLowChange": 25.053001, "fiftyTwoWeekLowChangePercent": 5.211775, "fiftyTwoWeekRange": "4.807 - 34.83", "fiftyTwoWeekHighChange": -4.970001, "fiftyTwoWeekHighChangePercent": -0.1426931, "fiftyTwoWeekChangePercent": 48.537098, "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-12-13"}]